Daidzein, R-(+)equol and S-(−)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2
Tóm tắt
Soy isoflavones may inhibit tumor cell invasion and metastasis via their effects on matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). The current study investigates the effects of daidzein, R- and S-equol on the invasion of MDA-MB-231 human breast cancer cells and the effects of these compounds on MMP/TIMP expression at the mRNA level. The anti-invasive effects of daidzein, R- and S-equol (0, 2.5, 10, 50 μM) on MDA-MB-231 cells were determined using the Matrigel invasion assay following 48-h exposure. Effects on MMP-2, MMP-9, TIMP-1 and TIMP-2 expression were assessed using real-time PCR. Chiral HPLC analysis was used to determine intracellular concentrations of R- and S-equol. The invasive capacity of MDA-MB-231 cells was significantly reduced (by approximately 50–60 %) following treatment with 50 μM daidzein, R- or S-equol. Anti-invasive effects were also observed with R-equol at 2.5 and 10 μM though overall equipotent effects were induced by all compounds. Inhibition of invasion induced by all three compounds at 50 μM was associated with the down-regulation of MMP-2, while none of the compounds tested significantly affected the expression levels of MMP-9, TIMP-1 or TIMP-2 at this concentration. Following exposure to media containing 50 μM R- or S-equol for 48-h intracellular concentrations of R- and S-equol were 4.38 ± 1.17 and 3.22 ± 0.47 nM, respectively. Daidzein, R- and S-equol inhibit the invasion of MDA-MB-231 human breast cancer cells in part via the down-regulation of MMP-2 expression, with equipotent effects observed for the parent isoflavone daidzein and the equol enantiomers.
Tài liệu tham khảo
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr (accessed October 2012)
Magee PJ, Rowland IR (2004) Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91:513–531
Steiner C, Arnould S, Scalbert A, Manach C (2008) Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 99:ES78–ES108
Yuan J-P, Wang J-H, Liu X (2007) Metabolism of dietary soy isoflavones to equol by human intestinal microflora—implications for health. Mol Nutr Food Res 51:765–781
Setchell KDR, Clerici C, Lephart E, Cole SJ, Heenan C et al (2005) S-equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 81:1072–1079
Lampe JW, Karr SC, Hutchins AM, Slavin JL (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 217:335–339
Rowland I, Wiseman H, Sanders TAB, Adlercreutz H, Bowey EA (2000) Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36:27–32
Setchell KDR, Cole SJ (2006) Method of defining equol-producer status and its frequency among vegetarians. J Nutr 136:2188–2193
Radisky ES, Radisky DC (2010) Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 15:201–212
Xu X, Wang Y, Chen Z, Sternlicht M, Hidalgo M, Steffensen B (2005) Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res 65:130–136
Deryugina E, Luo G, Reisfeld R, Bourdon M, Strongin A (1997) Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res 17:3201–3210
Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, Thiebaut C, Lemaire V, Dacquembronne E, Duhem T, Lebrun A, Dejonghe M, Huet G (2000) Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis 18:171–178
Azzam H, Arand G, Lippman M, Thompson E (1993) Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85:1758–1764
Ranogajec I, Jakic-Razumovic J, Puzovic V, Gabrilovac J (2011) Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol May 25 [Epub ahead of print]
Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I (2004) A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10:1057–1063
Rocca GL, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S (2004) Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 90:1414–1421
Shao Z, Wu J, Shen Z, Barsky S (1998) Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58:4851–4857
Magee PJ, McGlynn H, Rowland IR (2004) Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Lett 208:35–41
Magee PJ, Raschke M, Steiner C, Duffin JG, Pool-Zobel BL, Jokela T, Wahala K, Rowland IR (2006) Equol: A comparison of the effects of the racemic compound with that of the purified S-enantiomer on the growth, invasion, and DNA integrity of breast and prostate cells in vitro. Nutr Cancer 54:232–242
Kousidou OC, Mitropoulou TN, Roussidis AE, Kletsas D, Theocharis AD, Karamanos NK (2005) Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int J Oncol 26:1101–1109
Cailleau R, Young R, Olive M, Reeves W (1974) Breast tumour cell lines from pleural effusions. J Natl Cancer Inst 53:661–674
Mossman T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45
Yang Z, Strickland D, Bornstein P (2001) Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 276:8403–8408
(2011) Anti-invasion effects of R- and S-enantiomers of equol on prostate cancer PC3, DU145 cells. Wei Sheng Yan Jiu 40:423–430 (article in Chinese; no authors listed)
Zheng W, Zhang Y, Ma D, Shi Y, Liu C, Wang P (2012) (±) Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity. J Clin Biochem Nutr 51:61–67
Valachovicova T, Slivova V, Bergman H, Shuherk J, Sliva D (2004) Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kB/AP-1-dependent and -independent pathways. Int J Oncol 25:1389–1395
Brown NM, Belles CA, Lindley SL, Zimmer-Nechemias LD, Zhao X, Witte DP, Kim M-O, Setchell KDR (2010) The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis 31:886–893
Maubach J, Depypere HT, Goeman J, Van Der Eycken J, Heyerick A, Bracke ME, Blondeel P, De Keukeleire D (2004) Distribution of soy-derived phytoestrogens in human breast tissue and biological fluids. Obstet Gynecol 103:892–898
Bolca S, Urpi-Sarda M, Blondeel P, Roche N, Vanhaecke L, Possemiers S, Al-Maharik N, Botting N, De Keukeleire D, Bracke M, Heyerick A, Manach C, Depypere H (2010) Disposition of soy isoflavones in normal human breast tissue. Am J Clin Nutr 91:976–984
Setchell KDR, Brown NM, Zhao X, Lindley SL, Heubi JE, King EC, Messina MJ (2011) Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. Am J Clin Nutr 94:1284–1294